Results from a Randomized Study of REVLIMID® (Lenalidomide) and Rituximab (R2) in Patients with Recurrent Follicular Lymphoma Presented at ASCO
Yahoo/Business Wire
rituximab
news tags
Abbott Laboratories
Amgen
Arena Pharmaceuticals
AstraZeneca
Bayer
Biogen Idec
biotech
Boston Scientific
Bristol-Myers Squibb
cancer
Celgene
China
Dendreon
diabetes
earnings
Eli Lilly
Europe
FDA
generics
Genzyme
GSK
hepatitis C
investors
JNJ
lawsuits
layoffs
M&A
Management
Medtronic
Merck
Novartis
obesity
patents
Pfizer
prostate cancer
Roche
Sanofi
Teva Pharmaceuticals
vaccines
Vivus